{"id":"clopidogrel-abciximab","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Hypersensitivity reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Clopidogrel is a thienopyridine that irreversibly inhibits the P2Y12 adenosine diphosphate receptor on platelets, preventing platelet activation and aggregation. Abciximab is a chimeric monoclonal antibody that binds to the glycoprotein IIb/IIIa integrin receptor on platelets, blocking fibrinogen binding and platelet cross-linking. Together, they provide complementary antiplatelet mechanisms to prevent thrombotic events.","oneSentence":"This combination uses clopidogrel to inhibit platelet aggregation via P2Y12 receptor blockade and abciximab to block the glycoprotein IIb/IIIa receptor, providing dual antiplatelet effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:40:07.712Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome and percutaneous coronary intervention"}]},"trialDetails":[{"nctId":"NCT01103440","phase":"PHASE2","title":"Aspirin Resistance and Percutaneous Coronary Intervention (PCI)","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2007-04","conditions":"Stable Angina","enrollment":36},{"nctId":"NCT01475552","phase":"PHASE4","title":"Tailored Antiplatelet Therapy During Percutaneous Coronary Intervention in Patients With Diabetes Mellitus","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2010-09","conditions":"Diabetes Mellitus","enrollment":130},{"nctId":"NCT01158846","phase":"PHASE4","title":"Bivalirudin/Prasugrel Versus Abciximab/Clopidogrel in Patients Presenting With STEMI","status":"UNKNOWN","sponsor":"I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio","startDate":"2010-08","conditions":"ST-Elevation Myocardial Infarction, Primary Percutaneous Coronary Intervention","enrollment":800},{"nctId":"NCT00133250","phase":"PHASE4","title":"Value of Abciximab in Patients With AMI Undergoing Primary PCI After Clopidogrel Pretreatment (BRAVE 3)","status":"COMPLETED","sponsor":"Deutsches Herzzentrum Muenchen","startDate":"2003-06","conditions":"Myocardial Infarction","enrollment":800},{"nctId":"NCT00929279","phase":"PHASE4","title":"Efficacy of Abciximab Bolus Only Regimen in Providing Inhibition of Platelet Action Over Time","status":"COMPLETED","sponsor":"Università degli Studi di Ferrara","startDate":"2008-11","conditions":"Acute Coronary Syndrome","enrollment":73},{"nctId":"NCT00759629","phase":"PHASE4","title":"Beyond 12 Hours Reperfusion AlternatiVe Evaluation Trial","status":"COMPLETED","sponsor":"Deutsches Herzzentrum Muenchen","startDate":"2001-05","conditions":"Myocardial Infarction","enrollment":365},{"nctId":"NCT00133003","phase":"PHASE4","title":"Abciximab, Clopidogrel and Percutaneous Coronary Intervention in Acute Coronary Syndrome (ISAR-REACT-2)","status":"COMPLETED","sponsor":"Deutsches Herzzentrum Muenchen","startDate":"2003-03","conditions":"Coronary Disease, Angina, Unstable","enrollment":2022}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":275,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Plavix","ReoPro"],"phase":"marketed","status":"active","brandName":"clopidogrel/abciximab","genericName":"clopidogrel/abciximab","companyName":"I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio","companyId":"i-r-c-c-s-ospedale-galeazzi-sant-ambrogio","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses clopidogrel to inhibit platelet aggregation via P2Y12 receptor blockade and abciximab to block the glycoprotein IIb/IIIa receptor, providing dual antiplatelet effects. Used for Acute coronary syndrome and percutaneous coronary intervention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}